Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features

This study reports clinical, genetic, epigenetic, gene expression, and cellular features distinguishing meningioma DNA methylation subgroups within meningioma DNA methylation groups. We present these data in the context of molecular and clinical models predicting postoperative outcomes across 565 meningiomas with comprehensive clinical follow-up from independent discovery and validation institutions. By discovering meningioma DNA methylation subgroups within meningioma DNA methylation groups, we provide an opportunity to resolve inconsistencies in the recent literature. In doing so, our study establishes an architecture that unifies opposing biological theories for the most common primary intracranial tumor RNA-sequencing data is used to examine transcriptional signatures of meningioma subgroups in the context of methylation classification.

本研究报道了可用于区分脑膜瘤（meningioma）DNA甲基化分组内亚组的临床、遗传、表观遗传、基因表达及细胞特征。我们基于来自独立发现与验证机构的565例经全面临床随访的脑膜瘤样本，构建了可预测术后结局的分子与临床模型，并在此框架下呈现上述数据。通过在脑膜瘤DNA甲基化分组中鉴定亚组，本研究为解决近期文献中存在的观点不一致性提供了契机。在此基础上，本研究构建了可统一针对这一最常见原发性颅内肿瘤的对立生物学理论的分析架构；同时利用RNA测序（RNA-sequencing）数据，在甲基化分类的背景下探究脑膜瘤亚组的转录特征。